Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 7 | 2024 | 935 | 1.220 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 1502 | 0.570 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 643 | 0.550 |
Why?
|
| Toll-Like Receptors | 2 | 2020 | 51 | 0.530 |
Why?
|
| Immunity, Innate | 3 | 2024 | 149 | 0.470 |
Why?
|
| Health Status Disparities | 1 | 2019 | 642 | 0.440 |
Why?
|
| Patents as Topic | 1 | 2009 | 14 | 0.350 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2020 | 767 | 0.300 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2007 | 26 | 0.290 |
Why?
|
| Estrogen Receptor beta | 1 | 2007 | 40 | 0.290 |
Why?
|
| Estrogen Receptor alpha | 1 | 2007 | 111 | 0.280 |
Why?
|
| Genetics | 1 | 2006 | 9 | 0.270 |
Why?
|
| Estrogens | 1 | 2007 | 202 | 0.260 |
Why?
|
| Up-Regulation | 2 | 2008 | 513 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2009 | 807 | 0.260 |
Why?
|
| Curriculum | 1 | 2006 | 265 | 0.230 |
Why?
|
| Computational Biology | 1 | 2006 | 293 | 0.230 |
Why?
|
| Universities | 1 | 2006 | 442 | 0.210 |
Why?
|
| Signal Transduction | 2 | 2009 | 1908 | 0.200 |
Why?
|
| Minority Groups | 2 | 2021 | 596 | 0.180 |
Why?
|
| Cell Line, Tumor | 4 | 2019 | 2231 | 0.180 |
Why?
|
| Neoplasms | 1 | 2009 | 1103 | 0.170 |
Why?
|
| Humans | 12 | 2024 | 37093 | 0.170 |
Why?
|
| Genetic Variation | 2 | 2019 | 387 | 0.160 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2020 | 164 | 0.160 |
Why?
|
| Homeodomain Proteins | 2 | 2009 | 132 | 0.160 |
Why?
|
| Genotype | 1 | 2020 | 730 | 0.160 |
Why?
|
| Male | 7 | 2024 | 20025 | 0.150 |
Why?
|
| Body Size | 1 | 2017 | 32 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 628 | 0.140 |
Why?
|
| Inflammation | 1 | 2019 | 618 | 0.120 |
Why?
|
| Transcription Factors | 2 | 2009 | 681 | 0.120 |
Why?
|
| Receptor Cross-Talk | 1 | 2009 | 17 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1130 | 0.090 |
Why?
|
| Jamaica | 2 | 2020 | 11 | 0.090 |
Why?
|
| United States | 1 | 2019 | 4223 | 0.080 |
Why?
|
| Obesity | 1 | 2017 | 1067 | 0.080 |
Why?
|
| Receptors, Androgen | 1 | 2009 | 126 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 70 | 0.080 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2007 | 19 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 2379 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2020 | 661 | 0.070 |
Why?
|
| Virginia | 1 | 2006 | 10 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2008 | 1207 | 0.070 |
Why?
|
| Aged | 4 | 2020 | 6741 | 0.070 |
Why?
|
| Georgia | 1 | 2006 | 174 | 0.060 |
Why?
|
| Risk Factors | 3 | 2020 | 3562 | 0.060 |
Why?
|
| Female | 3 | 2019 | 20969 | 0.060 |
Why?
|
| Apoptosis | 1 | 2012 | 1398 | 0.060 |
Why?
|
| Internet | 1 | 2006 | 211 | 0.060 |
Why?
|
| Middle Aged | 4 | 2020 | 10129 | 0.060 |
Why?
|
| Time Factors | 1 | 2007 | 1742 | 0.050 |
Why?
|
| Adult | 3 | 2020 | 11712 | 0.050 |
Why?
|
| Students | 1 | 2006 | 519 | 0.050 |
Why?
|
| Trust | 1 | 2021 | 133 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 313 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2019 | 75 | 0.040 |
Why?
|
| Hela Cells | 1 | 2019 | 366 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 753 | 0.040 |
Why?
|
| Chemokines | 1 | 2017 | 97 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 893 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 123 | 0.030 |
Why?
|
| Cell Movement | 2 | 2009 | 571 | 0.030 |
Why?
|
| Adolescent | 1 | 2006 | 5363 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 602 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2721 | 0.030 |
Why?
|
| Entropy | 1 | 2012 | 13 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 275 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 180 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 269 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 67 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2009 | 76 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 176 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2009 | 81 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 923 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2009 | 156 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2009 | 133 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 623 | 0.020 |
Why?
|
| Mesoderm | 1 | 2008 | 70 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2008 | 191 | 0.020 |
Why?
|
| Cadherins | 1 | 2008 | 90 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 136 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 251 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 523 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 578 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 674 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2008 | 384 | 0.020 |
Why?
|